Clinical Trials - The Bloodline with Blood Cancer United Podcast

You cannot have progress without research.

In our latest episode, Dr. Jay Yang of the Karmanos Cancer Institute in Detroit, MI, breaks down the essentials of MDS care, from risk-based treatment plans to managing fatigue and exploring promising new therapies. Tune in to find out why the future of MDS treatment is brighter than ever.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Bristol Myers Squibb and Taiho Oncology, Inc.

The post Myelodysplastic Syndromes (MDS): Progress, Possibility, and What’s Next first appeared on The Bloodline with Blood Cancer United Podcast.

Behind every policy is a patient, caregiver, or family whose story helped make change possible.

In this episode, we speak with Andrea Sanchez and Becki Chandler, volunteer advocates with Blood Cancer United, about the power of patient voices in shaping public policy. Drawing from their own family experiences with blood cancer, they discuss issues ranging from medical debt and insurance coverage to clinical trial access and research funding and explain how patients and caregivers can make their voices heard.

Learn why sharing your story matters and how personal experiences help lawmakers see that patients are more than numbers on a page. Behind every statistic is a real person, a unique story, and a family impacted by blood cancer.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

The post Making Your Voice Count: The Power of Patient Advocacy first appeared on The Bloodline with Blood Cancer United Podcast.

When you hear the word “aggressive,” it can feel overwhelming, but in diffuse large B-cell lymphoma (DLBCL), it can also point to something encouraging – a potential cure.

In this episode, we speak with Dr. Jonathon Cohen, of Winship Cancer Institute in Atlanta, GA, about what a DLBCL diagnosis really means, from how this common type of non-Hodgkin lymphoma is identified to current treatment options and emerging therapies. We explain what patients and families need to know about side effects. We also look at new treatments, including CAR T-cell therapy and bispecific antibodies, and the importance of open communication with your care team.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Genmab US, Inc.

The post Diffuse Large B-Cell Lymphoma (DLBCL): Breaking Down an Aggressive Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.

What does a myelofibrosis (MF) diagnosis really mean, and how does it fit within a group of conditions called myeloproliferative neoplasms, or MPNs? In this episode, we’re joined by Dr. Tania Jain of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, who helps break it all down in a clear and approachable way.

She discusses how myelofibrosis affects the bone marrow, common symptoms to watch for, and how treatment options are tailored to each person. From managing day-to-day challenges to understanding when more advanced treatments may be considered, this conversation focuses on what matters most to patients and families.

As Dr. Jain shares, “every patient writes their own story,” noting that advancing research offers genuine hope.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Takeda Oncology.

The post Myelofibrosis (MF): More Options, More Hope first appeared on The Bloodline with Blood Cancer United Podcast.

Some people with chronic lymphocytic leukemia (CLL) may feel well day to day, but that doesn’t mean life stays the same. In this episode, we hear from Annette Holloway, a clinical psychologist living with CLL, as she shares how her diagnosis, treatment decisions, and side effects have shaped her daily life. Also joining us is Elise Curry, RN, OCN, a Clinical Trial Nurse Navigator at Blood Cancer United’s Clinical Trial Support Center, who helps break down treatment options, side effects, and the importance of communication with your care team.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by AbbVie Inc.; BeOne Medicines; and Genentech, A Member of the Roche Group.

The post Chronic Lymphocytic Leukemia (CLL): Managing Treatment and Finding Balance first appeared on The Bloodline with Blood Cancer United Podcast.

Acute myeloid leukemia (AML) is a complex diagnosis, and it can be difficult to know what to expect in those early conversations after diagnosis. In this episode, we speak with Dr. Rebecca Olin from the University of California, San Francisco (UCSF), who helps explain what AML is and how care is approached today.

Dr. Olin walks us through how doctors evaluate AML, what factors influence treatment decisions, and how therapies – including targeted treatments, stem cell transplant, and clinical trials – are helping improve outcomes and quality of life. We also discuss the importance of supportive care and ongoing research, offering listeners a clearer picture of how AML is treated now and where progress continues to be made.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Astellas Pharma US Inc.; Daiichi Sankyo Inc.; Debiopharm; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.

The post Acute Myeloid Leukemia (AML): New Approaches For A Complex Diagnosis first appeared on The Bloodline with Blood Cancer United Podcast.

Multiple myeloma can feel unfamiliar and overwhelming at first, but today’s advances tell a much brighter story.

In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it’s diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights how patients may progress from periods of significant challenges to reaching a level of stability and well‑being that allows them to live fully. This conversation offers clarity, confidence, and real optimism for anyone navigating myeloma.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by AbbVie Inc.; Bristol Myers Squibb; Genentech, A Member of the Roche Group; GSK plc.; Johnson & Johnson.

The post Facing Multiple Myeloma: A Guide to Choices, Care, and Confidence first appeared on The Bloodline with Blood Cancer United Podcast.

CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families.

In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advancements shaping the future of this innovative therapy.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech;  Kite, a Gilead Company; Novartis Pharmaceuticals Corporation.

The post Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives first appeared on The Bloodline with Blood Cancer United Podcast.

Cutaneous T‑cell lymphoma (CTCL) is a rare condition that often raises important questions for patients and families.

In this episode, we sit down with Dr. Stefan Barta, of the University of Pennsylvania, to bring clarity to what CTCL is, how it’s diagnosed, and what patients can expect from staging and treatment. Dr. Barta breaks down the differences between CTCL subtypes, explains why diagnosing someone can take time, and shares the most up-to-date therapies, including skin directed treatments, immunotherapies, and emerging clinical trial options. Most importantly, he offers reassurance for those newly diagnosed: “The future is absolutely bright… there is a lot of hope for our patients with CTCL.”

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Kyowa Kirin, Inc. and Cutaneous Lymphoma Foundation.

The post Cutaneous T-Cell Lymphoma (CTCL): Illuminating a Brighter Path Forward first appeared on The Bloodline with Blood Cancer United Podcast.

Curious about what’s new in the world of myelodysplastic syndromes (MDS)? We’re bringing you the latest insights straight from one of the field’s leading experts.

In this episode, we speak with Dr. Mikkael Sekeres, of the Sylvester Comprehensive Cancer Center at University of Miami Health. Recorded onsite at the 2025 ASH (American Society of Hematology) Annual Meeting and Exposition, this conversation explores what MDS is, how it’s treated today, and what researchers are learning about managing side effects.

Dr. Sekeres also walks us through the most notable MDS updates presented at ASH, highlighting promising therapies and clinical trial data that may help shape future care. Whether you’re newly learning about MDS or following ongoing research, this episode offers an accessible look at where things stand and what’s on the horizon.

*This is not an official program of the ASH annual meeting

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Geron Corporation and Taiho Oncology, Inc.

The post The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research first appeared on The Bloodline with Blood Cancer United Podcast.